Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

by A. Hochhaus, G. Saglio, T. P. Hughes, R. A. Larson, D. W. Kim, S. Issaragrisil, P. D. Le Coutre, G. Etienne, P. E. Dorlhiac-Llacer, R. E. Clark, I. W. Flinn, H. Nakamae, B. Donohue, W. Deng, D. Dalal, H. D. Menssen, H. M. Kantarjian
Published 2018